CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-10-12): Iodine-131 lipiodol offers palliation in hepatocellular carcinoma

Clinical

Iodine-131 lipiodol offers palliation in hepatocellular carcinoma

Last Updated: 2005-10-12 14:43:06 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Metabolic radiotherapy with I-131-lipiodol (Lipiocis) provides meaningful survival in some patients with advanced hepatocellular carcinoma (HCC), researchers in Belgium report.

"Patients with well preserved liver function, advanced HCC, and portal vein thrombosis could benefit from Lipiocis as no embolization is performed," Dr. Yves Horsmans from Universite Catholique de Louvain, Brussels, told Reuters Health.

Dr. Horsmans and associates investigated the feasibility, tolerance, and efficacy of I-131-lipiodol in 29 patients with advanced multifocal tumors not amenable to surgery, transplantation, percutaneous treatments, or chemo-embolization.

Nine patients had two courses of I-131-lipiodol, and one patient had three courses, according to the report, published in the September European Journal of Gastroenterology and Hepatology.

The median survival was 203 days, the authors report. Patients with Cancer of the Liver Italian Program (CLIP) scores of 2 or less had significantly longer median survival (453 days) than did patients with CLIP scores above 2 (60 days).

Patients without portal vein thrombosis had higher 6-month survival (75%) than did patients with portal vein thrombosis (25%), the results indicate.

Tumor response as assessed by MRI in 19 patients revealed a partial response in 1 patient, stable disease in 10 patients, and progressive disease in 8 patients.

Alpha-fetoprotein and Child-Pugh scores did not differ meaningfully after treatment, the researchers note.

The patients tolerated treatment well, the investigators report, with all but one patient experiencing only moderate fever and mild asthenia. Severe complications included two cases of interstitial pneumonia and one upper digestive hemorrhage as a result of bleeding esophageal varices.

Two patients died, one with interstitial pneumonia and one with acute liver failure, for a treatment-related mortality of 6.9%.

"In our series, I-131-lipiodol seemed to give the same survival rates as those observed in the published data for portal vein thrombosis-negative patients or those known for patients with similar CLIP scores," the authors explain.

"The CLIP score should be used to select patients who could benefit from I-131-lipiodol, and have a better survival," the investigators conclude. "There is no benefit in subjecting patients with a CLIP score greater than 2 to I-131-lipiodol therapy."

"Otherwise, at this stage, our data do not support the use of Lipiocis instead of chemo-embolization in Child-Pugh A or B patients," Dr. Horsmans added.

Eur J Gastroenterol Hepatol 2005;17:905-910.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.